search
Back to results

Ivermectin in the Treatment of Head Lice

Primary Purpose

Lice Infestations

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
ivermectin
malathion
Sponsored by
Johnson & Johnson Consumer and Personal Products Worldwide
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lice Infestations focused on measuring pediculosis capitis, pediculus

Eligibility Criteria

2 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Head lice infestation confirmed by detection combing by study staff
  • previous (within 6 weeks) use of a topical insecticide product
  • minimum 15kg weight
  • providing informed consent

Exclusion Criteria:

  • pregnant or nursing patients
  • households with 7 or more infested patients
  • households where there are other known infested household members not participating
  • head lice treatment within 2 weeks of entry
  • active scalp infection
  • any difficulty with combing assessment
  • patient from region endemic for certain parasitic worm diseases

Sites / Locations

  • Hopital Avicenne
  • Shandon Clinic
  • Chaim Sheba Medical Centre
  • Synexus Clinical Research Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Ivermectin

Malathion

Arm Description

ivermectin Stromectol®)

malathion(Prioderm®)

Outcomes

Primary Outcome Measures

Absence or presence of live head lice

Secondary Outcome Measures

Absence or presence of live head lice at alternative Study Days.
Safety Assessments will consist of monitoring and recording all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product.

Full Information

First Posted
January 8, 2009
Last Updated
August 19, 2011
Sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
search

1. Study Identification

Unique Protocol Identification Number
NCT00819520
Brief Title
Ivermectin in the Treatment of Head Lice
Official Title
A Randomised, Double-Blind, Multicentre Study to Compare the Efficacy and Tolerability of Oral Ivermectin to Malathion 0.5% Lotion in the Treatment of Head Lice Infestation
Study Type
Interventional

2. Study Status

Record Verification Date
August 2011
Overall Recruitment Status
Completed
Study Start Date
February 2004 (undefined)
Primary Completion Date
September 2004 (Actual)
Study Completion Date
October 2004 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johnson & Johnson Consumer and Personal Products Worldwide

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare 2 single doses of ivermectin as tablets with 2 single applications of malathion 0.5% lotion (Days 1 and 8) in clearing head lice, in patients who have recently used standard head lice treatments without success.
Detailed Description
Head lice infestation occurs frequently, primarily in children 3 to 11 years of age. In recent years an increasing prevalence of lice infestation in schools, day care centres, and summer day camps is believed to be partly due to increasing lice resistance to currently available standard treatments for pediculosis (infestation with lice). There is a need for new effective backup treatments for this common condition of head lice infestation. This is a double-blind, randomized, parallel-group, study in several clinical centres comparing ivermectin as tablets to malathion 0.5% lotion in the treatment of head lice. All enrolled patients participate in the primary phase of the study up to the Day 15 evaluation. Patients who are still infested with lice at Day 15 (treatment failures) will enter an extension phase and be treated in a double-blind, fashion with the opposite treatment (ie ivermectin or malathion). The study hypothesis is that ivermectin will be more effective than malathion in clearing head lice infestation , as measured by the proportion of patients who are lice-free at Study Day 15.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lice Infestations
Keywords
pediculosis capitis, pediculus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
812 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ivermectin
Arm Type
Experimental
Arm Description
ivermectin Stromectol®)
Arm Title
Malathion
Arm Type
Active Comparator
Arm Description
malathion(Prioderm®)
Intervention Type
Drug
Intervention Name(s)
ivermectin
Other Intervention Name(s)
Stromectol®
Intervention Description
Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
Intervention Type
Drug
Intervention Name(s)
malathion
Other Intervention Name(s)
Prioderm®
Intervention Description
Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
Primary Outcome Measure Information:
Title
Absence or presence of live head lice
Time Frame
Study Day 15
Secondary Outcome Measure Information:
Title
Absence or presence of live head lice at alternative Study Days.
Time Frame
Study Days 2, 8, 22, 29
Title
Safety Assessments will consist of monitoring and recording all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product.
Time Frame
throughout duration of the study (+ 30 days for spontaneously reported SAEs)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Head lice infestation confirmed by detection combing by study staff previous (within 6 weeks) use of a topical insecticide product minimum 15kg weight providing informed consent Exclusion Criteria: pregnant or nursing patients households with 7 or more infested patients households where there are other known infested household members not participating head lice treatment within 2 weeks of entry active scalp infection any difficulty with combing assessment patient from region endemic for certain parasitic worm diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jerry Cottrell
Organizational Affiliation
J&J Consumer and Personal Products Worldwide
Official's Role
Study Director
Facility Information:
Facility Name
Hopital Avicenne
City
Bobigny
State/Province
Paris
ZIP/Postal Code
93009
Country
France
Facility Name
Shandon Clinic
City
Cork
State/Province
Co. Cork
Country
Ireland
Facility Name
Chaim Sheba Medical Centre
City
Tel Hashomer
ZIP/Postal Code
52621
Country
Israel
Facility Name
Synexus Clinical Research Centre
City
Reading
State/Province
Berks
ZIP/Postal Code
RG2 7AG
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
20220184
Citation
Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, Burgess I. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med. 2010 Mar 11;362(10):896-905. doi: 10.1056/NEJMoa0905471. Erratum In: N Engl J Med. 2010 Apr 29;362(17):1647.
Results Reference
derived

Learn more about this trial

Ivermectin in the Treatment of Head Lice

We'll reach out to this number within 24 hrs